<DOC>
	<DOCNO>NCT01567683</DOCNO>
	<brief_summary>This study design assess tolerability test product vehicle term skin reaction repeat topical application healthy skin control condition basis international guideline test skin irritation ( FDA Guidance Industry ( 1999 ) ) .</brief_summary>
	<brief_title>A Double-blind , Randomized , Single Centre , Vehicle-controlled Study Evaluate Safety Tolerability New Topical Formulation Containing 0,09 % Imiquimod ( Limtop ) Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Imiquimod</mesh_term>
	<criteria>1 . The write informed consent form ( ICF ) sign date subject prior studyrelated activity 2 . Generally healthy male female subject age â‰¥ 18 year 3 . Healthy skin treatment area ( inner site forearm ) test field positive control upper arm 4 . Skin type IIII ( Fitzpatrick ) 5 . Willingness actively participate study comply study procedure define study protocol 6 . High probability good compliance orderly completion study 7 . Female subject childbearing potential must use highly effective method contraception 8 . Negative urine pregnancy test ( female subject childbearing potential ) 1 . Pregnant breastfeed woman 2 . Known suspected skin disease ( e.g . acne vulgaris , atopic dermatitis , psoriasis , etc . ) , might interfere evaluation skin reaction treatment area SLS test field 3 . Clinical history suggestive intolerance , allergies idiosyncrasy one IMPs ingredient product ( butyl lactate , isopropyl myristate , propylene glycol , butylate hydroxy anisole ) suspect cross allergy 4 . Known skin allergy 5 . Known infectious disease ( e.g . HIV , hepatitis ) discretion investigator 6 . Insulin dependent diabetes 7 . Psychiatric condition might limit participation trial / lead assumption ability completely understand consequence consent miss 8 . Any suspicion drug / alcohol abuse within past 5 year 9 . Any illness circumstance could affect trial purpose opinion investigator 10 . Within 1 week prior Day 1 whole study systemic use antihistamine 11 . Within 4 week prior Day 1 entire study change medication common medical influence skin perfusion ( e.g . betablockers ) 12 . Within 4 week prior Day 1 entire trial use systemic medication likely interfere trial purpose ( e.g . immunemodulating therapy , corticosteroid , cytotoxics immunosuppressant ) 13 . Within 2 week prior Day 1 entire trial : dermatological medication ( drug medical device ) treatment area SLS test field ( exception : symptomatic treatment discontinue area topical treatment decide investigator ) 14 . Use cosmetic product ( e.g . cream , moisturizers ) treatment area ( i.e . inner forearm ) SLS test field within 5 day prior Day 1 throughout treatment phase ( Day 1 Day 22 ) 15 . Intensive UVlight exposure ( e.g . solarium visit ) within 4 week Day 1 well study 16 . Moles , tattoo , pigmentation scar application area ( arm ) would influence visual score 17 . Participation another clinical trial within 30 day directly precede study , entire study , early participation study 18 . Employees study site Sponsor 's company</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Safety Tolerability Limtop vehicle</keyword>
	<keyword>Limtop vehicle</keyword>
</DOC>